RUA LIFE SCIENCES PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.75 GBX | +4.88% |
|
-2.27% | +9.14% |
| Apr. 05 | RUA Life Sciences expects flat annual revenue on strong second half | AN |
| Apr. 05 | RUA Life Sciences plc Provides Revenue Guidance for the Year Ended 31 March 2024 | CI |
Presentation Operator MessageOperator (Operator)Thank you for those of you who are joining us ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
RUA Life Sciences plc is a United Kingdom-based holding company of a group of medical device businesses focused on the exploitation of long-term implantable biostable polymer (Elast-Eon). Elast-Eon's biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. The Company has four business units: RUA Contract Manufacture, RUA Biomaterials, RUA Vascular and RUA Structural Heart. RUA Contract Manufacture is an end-to-end contract developer and manufacturer of medical devices and implantable fabric specialist. It provides sub-contract manufacturing, assembly, packing and services to the medical device sector from its Class 7 and 8 cleanroom suites. RUA Biomaterials is a licensor of Elast-Eon polymers to the medical device industry. RUA Vascular is engaged in the commercialization of open surgical vascular grafts and patches. RUA Structural Heart is engaged in the development of polymeric leaflet systems for heart valves.
Calendar
2024-07-16
- Q4 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +9.14% | 8.31M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B | |
| +26.76% | 32.03B |
- Stock Market
- Equities
- AOR Stock
- News RUA Life Sciences plc
- Transcript : RUA Life Sciences plc, Q2 2024 Earnings Call, Dec 19, 2023
